BioSpace News Archive

According to Vision Research Reports, the global medical enzyme technology market size was valued at US$ 4.37 billion in 2021 and it is expected to hit around US$ 7.38 billion by 2030. It is projected to expand at a CAGR of 6% during the forecast period 2022-2030.

According to the Vision Research Reports, the global neuropathic pain therapeutics market size surpassed US$ 6.58 billion in 2021 and to reach US$ 10.21 billion by 2030 with a CAGR of 5% from 2022 to 2030.

The global Ophthalmic Drugs market size is expected to be worth around US$ 70.5 billion by 2030, according to a new report by Vision Research Reports.

The global MiRNA Sequencing And Assay market size is expected to be worth around US$ 600.8 Mn by 2030, according to a new report by Vision Research Reports

The global glioblastoma multiforme treatment market size is expected to hit around US$ 10.2 billion by 2030, according to a new report by Vision Research Reports.

The global in-vitro inflammatory bowel disease diagnostic market size was surpassed US$ 1.69 Billion in 2021 and is expected to reach around USD 2.41 billion by 2030 with a CAGR of 4% from 2022 to 2030.

The global immunotherapy drugs market size was estimated at USD 110.74 billion in 2021 and it is expected to surpass around USD 200.62 billion by 2030, poised to grow at a CAGR of 6.83% from 2022 to 2030

AbbVie (NYSE: ABBV) today announced it would present new data across its rheumatology portfolio, including RINVOQ® (upadacitinib) for rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, and SKYRIZI® (risankizumab) for psoriasis and psoriatic arthritis at the American College of Rheumatology’s annual meeting (ACR Convergence 2022).

Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in three upcoming investor conferences.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced financial results for the third quarter of 2022, and associated Company developments.